Get started
Author

Apurna Jegannathen

Observed names: A JEGANNATHEN, A Jegannathen, A. Jegannathen, Jegannathen Apurna
Observed institutions: National Health Service, University Hospitals of North Midlands NHS Trust, Beatson West of Scotland Cancer Centre, Royal Stoke University Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Keele University
ORCID: 0000-0002-4606-6924
Observed ORCID: 0000-0002-4606-6924
OpenAlex ID: A5036095330
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 522
PDF
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
2019 · Helena M Earl, Louise Hiller, et al. · The Lancet · 300
PDF
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
2019 · Neil Bayman, Wiebke Appel, et al. · Journal of Clinical Oncology · 66
Striking lung cancer response to self-administration of cannabidiol: A case report and literature review
2019 · Josep Sulé-Suso, Nick A Watson, et al. · SAGE Open Medical Case Reports · 38
PDF
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer
2022 · Thomas Bachelot, Paul Cottu, et al. · Journal of Clinical Oncology · 34
Synchronous Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck using Capecitabine: a Single-centre, Open-label, Single-group Phase II Study
2010 · A. Jegannathen, K. Mais, et al. · Clinical Oncology · 17
Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
2021 · K. Banfill, W. Croxford, et al. · Clinical Oncology · 14
PDF
Parotid gland: an unusual site of breast cancer metastasis
2017 · Thomas Rawet, Apurna Jegannathen, et al. · BMJ Case Reports · 10
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
Real-world data of using durvalumab in stage III non-small cell lung cancer (NSCLC): West Midlands experience
2020 · A. Jegannathen · Lung Cancer · 7
Testicular seminoma with mediastinal lymphadenopathy — a diagnostic pitfall
2009 · A JEGANNATHEN, M B TAYLOR, et al. · British Journal of Radiology · 7
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
2024 · F. Penault-Llorca, F. Dalenc, et al. · ESMO Open · 6
Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review
2013 · Shahid Nazir Gilani, Rebecca Gridley, et al. · BMJ Case Reports · 5
PDF
Can Synchronous Chemotherapy be Added to Accelerated Hypofractionated Radiotherapy in Patients with Base of Tongue Cancer?
2010 · A. Jegannathen, R. Swindell, et al. · Clinical Oncology · 5
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study
2022 · Mariam Jafri, Hartmut Kristeleit, et al. · Oncology · 4
PDF
P0054 Maintenance therapy with pemetrexed immediately following induction treatment with pemetrexed plus cisplatin for advanced non-small-cell non-squamous carcinoma of the lung: A single institution’s experience
2015 · D.H. Kim, A. Kinmond, et al. · European Journal of Cancer · 4
Abstract PS3-11-21: A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: interim results from the NERLYFE study
2026 · D. Baerens, A. Waqas, et al. · Clinical Cancer Research · 1
82 Implementing the neoadjuvant chemotherapy+Nivolumab pathway for patients with resectable Non-Small Cell Lung Cancer (NSCLC)- A single UK center experience (UHNM-Stoke On Trent)
2024 · Apurna Jegannathen, Alina Budacan, et al. · Lung Cancer · 1
Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK
2023 · I. Fornacon-Wood, K. Banfill, et al. · Clinical Oncology · 1
Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)
2022 · Frederique Penault-Llorca, Florence Dalenc, et al. · Cancer Research · 1
203MO Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung)
2021 · K. Banfill, G. Price, et al. · Journal of Thoracic Oncology · 1
PDF
A Sustained Response of Maintenance Therapy in Pancreatic Acinar Cell Carcinoma (PACC): A Case Report and Literature Review
2020 · Shahid Gilani, Apurna Jegannathen · Acta Scientific Cancer Biology · 1
PDF
Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience
2018 · N. Yoganayagam, A. Tripathy, et al. · European Journal of Cancer · 1
Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
2015 · D. H. Kim, A. Kinmond, et al. · Forum of Clinical Oncology · 1
PDF
59: Maintenance pemetrexed immediately following induction treatment with pemetrexed plus cisplatin for advanced non-small-cell non-squamous carcinoma of the lung – a single institution experience
2015 · D. Kim, S.N. Gilani, et al. · Lung Cancer · 1
Works count: 57
Citation count: 1,067
H-index: 9
I10-index: 8
Year
Topic
Type